Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITE DE PARIS has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 2 examiners and 2 art units, indicating separate prosecution contexts.
QIAN, CELINE X is the busiest examiner, with 1 pending action. Counsel should coordinate the scientific position across the portfolio while adapting arguments to each examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| §112 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246270 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | QIAN, CELINE X | 29d |
| 19196172 | ANTIBODIES HAVING SPECIFICITY FOR CD38 AND USES THEREOF | CHATTIN, AMY MARIE | — |
| 17440351 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | EDGINGTONGIORDANO, FRANCESCA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19196172 | ANTIBODIES HAVING SPECIFICITY FOR CD38 AND USES THEREOF | CHATTIN, AMY MARIE | 1643 | §112Other | Final Rejection | — | Pending | May 01, 2025 |
| 18246270 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | QIAN, CELINE X | 1637 | §103 | Final Rejection | 29d | Pending | Mar 22, 2023 |
| 17440351 | USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103 | Non-Final OA | — | Pending | Sep 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE DE PARIS has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Amy Marie Chattin has the most, with 1 of UNIVERSITE DE PARIS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
